Medite Cancer Diagnostics, Inc.

Total Valuation

Medite Cancer Diagnostics, Inc. carries a market capitalization of 8,672.00, placing it among publicly traded companies globally. Its enterprise value stands at 18.06M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Medite Cancer Diagnostics, Inc. currently has 74.65M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 1.37, and the price-to-book ratio stands at -1.03.

Enterprise Valuation

Financial Position

Medite Cancer Diagnostics, Inc. maintains a current ratio of 1.11, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 94.00, indicating elevated leverage, while an interest coverage ratio of -3.12 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Stock Price Statistics

Medite Cancer Diagnostics, Inc.'s stock has gained approximately 0.000003% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.

Income Statement

Over the trailing twelve months, Medite Cancer Diagnostics, Inc. generated 8.13M in revenue and converted that into -5.33M in net income, yielding earnings per share of -0.10. EBITDA reached -3.73M, while operating income came in at -4.01M.

Balance Sheet

Medite Cancer Diagnostics, Inc. holds 90,000.00 in cash and equivalents against 6.05M in total debt, resulting in a net debt position of 5.96M. Total book value stands at -10.82M, with working capital of 526,000.00 providing operational flexibility.

Cash Flow

Medite Cancer Diagnostics, Inc. produced -5.19M in operating cash flow over the past twelve months. After subtracting -106,000.00 in capital expenditures, free cash flow totaled -5.30M - equivalent to -0.10 per share.

Margins

Medite Cancer Diagnostics, Inc. operates with a gross margin of 23.71, reflecting its pricing power and cost economics. The operating margin of -49.34 and net profit margin of -65.49 provide insight into operational efficiency.

Dividends & Yields

The company's payout ratio of 1.68 indicates the proportion of earnings distributed to shareholders.

Stock Splits

Medite Cancer Diagnostics, Inc.'s most recent stock split took place on March 12, 2015 with a 100:1 split ratio.

Scores

Medite Cancer Diagnostics, Inc. posts an Altman Z-Score of -2.17, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.